Jiangsu Kanion Pharmaceutical Co (SHSE:600557) COGS-to-Revenue : 0.26 (As of Mar. 2025)

View and export this data going back to 2002. Start your Free Trial

What is Jiangsu Kanion Pharmaceutical Co COGS-to-Revenue?

Jiangsu Kanion Pharmaceutical Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥227 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥878 Mil.

Jiangsu Kanion Pharmaceutical Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.26.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Jiangsu Kanion Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 was 74.18%.

Jiangsu Kanion Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Jiangsu Kanion Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Kanion Pharmaceutical Co COGS-to-Revenue Chart

Jiangsu Kanion Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.27

0.28

0.26

0.27

Jiangsu Kanion Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.25	0.26	0.27	0.31	0.26

Jiangsu Kanion Pharmaceutical Co COGS-to-Revenue Calculation

Jiangsu Kanion Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1043.898	/	3897.669
	=	0.27

Jiangsu Kanion Pharmaceutical Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	226.572	/	877.554
	=	0.26

Jiangsu Kanion Pharmaceutical Co (SHSE:600557) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Jiangsu Kanion Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	226.572 / 877.554
	=	74.18 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Jiangsu Kanion Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Jiangsu Kanion Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Kanion Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Kanion Pharmaceutical Co Ltd (SHSE:600557) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

No. 58 Haichang South Road, Xinpu District, Jiangsu, Lianyungang, CHN, 222001

Website

http://www.kanion.com

Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.

Executives

Pan Yu	Director
Wang Chuan Lei	Director
Yang Yong Chun	Director
Liu Quan	Director
Wang Zhen Zhong	Director
Chen Xue Bin	Director
Xu Dian Hong	Director
Wu Yun	Director
Gao Hai Xin	Director
Xiao Wei	Director
Wan Yan Huan	senior management
Xia Yue	Director
Yang Yin	Director

Jiangsu Kanion Pharmaceutical Co Headlines

No Headlines